1. Home
  2. OBK vs COLL Comparison

OBK vs COLL Comparison

Compare OBK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBK
  • COLL
  • Stock Information
  • Founded
  • OBK 1912
  • COLL 2002
  • Country
  • OBK United States
  • COLL United States
  • Employees
  • OBK N/A
  • COLL N/A
  • Industry
  • OBK Major Banks
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBK Finance
  • COLL Health Care
  • Exchange
  • OBK Nasdaq
  • COLL Nasdaq
  • Market Cap
  • OBK 1.1B
  • COLL 1.1B
  • IPO Year
  • OBK 2018
  • COLL 2015
  • Fundamental
  • Price
  • OBK $32.73
  • COLL $29.70
  • Analyst Decision
  • OBK Buy
  • COLL Strong Buy
  • Analyst Count
  • OBK 5
  • COLL 6
  • Target Price
  • OBK $36.80
  • COLL $42.00
  • AVG Volume (30 Days)
  • OBK 159.8K
  • COLL 508.5K
  • Earning Date
  • OBK 01-22-2025
  • COLL 02-20-2025
  • Dividend Yield
  • OBK 1.83%
  • COLL N/A
  • EPS Growth
  • OBK N/A
  • COLL 757.11
  • EPS
  • OBK 2.43
  • COLL 2.16
  • Revenue
  • OBK $343,330,000.00
  • COLL $599,245,000.00
  • Revenue This Year
  • OBK N/A
  • COLL $13.20
  • Revenue Next Year
  • OBK $3.76
  • COLL $17.63
  • P/E Ratio
  • OBK $13.49
  • COLL $13.73
  • Revenue Growth
  • OBK N/A
  • COLL 9.62
  • 52 Week Low
  • OBK $27.69
  • COLL $28.97
  • 52 Week High
  • OBK $37.56
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • OBK 36.41
  • COLL 40.90
  • Support Level
  • OBK $35.65
  • COLL $29.48
  • Resistance Level
  • OBK $36.72
  • COLL $31.14
  • Average True Range (ATR)
  • OBK 1.16
  • COLL 1.10
  • MACD
  • OBK -0.48
  • COLL 0.14
  • Stochastic Oscillator
  • OBK 1.88
  • COLL 9.91

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: